医学
肺栓塞
溶栓
危险分层
重症监护医学
心脏病学
心肌梗塞
出处
期刊:Clinical Medicine
[Royal College of Physicians]
日期:2019-05-01
卷期号:19 (3): 243-247
被引量:51
标识
DOI:10.7861/clinmedicine.19-3-247
摘要
ABSTRACT
Pulmonary embolism, despite being common, often remains elusive as a diagnosis, and clinical suspicion needs to remain high when seeing a patient with cardiopulmonary symptoms. Once suspected, diagnosis is usually straightforward; however, optimal treatment can be difficult. Risk stratification with clinical scores, biomarkers and imaging helps to refine the best treatment strategy, but the position of thrombolysis in intermediate risk (submassive) pulmonary embolism remains a grey area. Pulmonary embolism response teams are on the increase to provide advice in such cases. Direct oral anticoagulants have been a major advance in treatment this decade, but are not appropriate for all patients. Follow-up of patients with pulmonary embolism should be mandatory to determine duration of anticoagulation and to assess for serious long-term complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI